Clinical Trials
36 trialsEntinostat Neuroendocrine (NE) Tumor
Columbia University
NELMAS
Imperial College London
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lu-Ca-S
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
University of Iowa
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
Telotristat With Lutathera in Neuroendocrine Tumors
University of Kentucky
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
Pembro NEC
University of Utah
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Vanderbilt-Ingram Cancer Center
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
DOTA-TOC
University of California, San Francisco
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
AHS Cancer Control Alberta
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
TERAVECT
GERCOR - Multidisciplinary Oncology Cooperative Group
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Stanford University
GaIN
Insel Gruppe AG, University Hospital Bern
LOTUS
National Cancer Institute, Naples
NET
Assistance Publique - Hôpitaux de Paris
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute